TAG1 and PharmaLogic Join Forces to Enhance Radiopharmaceutical Development with Lead-212 Generators
TAG1 Inc., a leading supplier of medical isotopes, has recently declared a significant strategic partnership with PharmaLogic, a renowned contract development and manufacturing organization (CDMO) that specializes in radiopharmaceuticals. This collaboration marks a transformative milestone aimed at accelerating the development of TAG1's proprietary Lead-212 (Pb-212) generator platform, thereby expanding its market reach and supporting PharmaLogic's ongoing initiatives to improve the availability of alpha-emitting isotopes.
Over the last 18 months, TAG1 has diligently prototyped and incubated its generator design at esteemed facilities such as the Missouri University Research Reactor (MURR) and the Massachusetts Institute of Technology's Innovation Center (MITC). With the TAG1 Board's formal endorsement of the final clinical design, the company is poised to transition into the scaling and production phases. This strategy will allow TAG1 to provide high-purity Pb-212 through a decentralized, on-site generator model targeting radiopharmacies, hospitals, and therapeutic developers.
Sumit Verma, the CEO and Founder of TAG1, expressed optimism about the partnership, stating, "This collaboration with PharmaLogic is a defining step forward as we scale our Pb-212 generator technology. PharmaLogic's operational strength and commitment to innovation make them an ideal partner as we move from concept to clinic with a solution that supports both emerging and established radiotherapeutic programs."
The design of TAG1's Pb-212 generator closely resembles established models in nuclear medicine, enabling the on-demand, localized production of Pb-212. This decentralized model is crucial for alleviating supply bottlenecks associated with isotopes, especially as biopharmaceutical companies increasingly explore Pb-212-based therapies for oncology and rare diseases.
PharmaLogic's President and CEO, Etienne Montagut, shared his enthusiasm about the alliance, stating, "We're thrilled to support TAG1's next phase of growth and help expand access to alpha-emitting isotopes like Pb-212. As the demand for targeted radiotherapeutics surges, strategic partnerships are vital for connecting innovation with clinical delivery."
Having extensive expertise in radiopharmaceutical development, regulatory adherence, and large-scale manufacturing throughout North America, PharmaLogic is well-equipped to provide the operational support necessary for TAG1 to progress from prototype development to clinical-grade generator production. The firms will closely collaborate with pharmaceutical partners, academic institutions, and early innovators to ensure the on-demand delivery of preclinical and clinical quantities of Pb-212. This will be pivotal in supporting the next wave of advancements in targeted alpha therapy.
About TAG1 Inc.
TAG1 Inc. stands out as a prominent supplier of medical isotopes, particularly focusing on the production of Lead-212 (Pb-212) intended for use in Targeted Alpha Therapies (TATs). Their proprietary generator system is an innovative tool designed to unlock Pb-212 supplies for preclinical and clinical trials concerning targeted alpha therapies. Committed to revolutionizing cancer treatment via groundbreaking nuclear medicine, TAG1 Inc. aims to enhance the radiopharmaceutical supply chain and facilitate the development of cutting-edge therapies. Explore more at www.tag1inc.com and follow them on LinkedIn for updates.
About PharmaLogic Holdings Corp.
As a pioneering global CDMO, PharmaLogic specializes in both diagnostic and therapeutic radiopharmaceuticals. With decades of industry expertise and a vast network consisting of over 45 facilities across the U.S., Puerto Rico, Canada, and Norway, PharmaLogic offers all-encompassing solutions from development to manufacturing and distribution of both clinical and commercial-stage radiopharmaceutical products, adhering to the highest quality and regulatory standards. Their rapidly growing diagnostics business leverages cutting-edge technologies to improve patient access to novel diagnostics in critical areas such as oncology, cardiology, and neurology. In the therapeutic sector, PharmaLogic has secured its position as the only cGMP-compliant CDMO globally that manufactures and distributes a commercial radiopharmaceutical therapeutic to more than 30 countries. Dedicated to enhancing global patient access to radiopharmaceuticals, PharmaLogic pursues strategic development partnerships with industry innovators, driving the field's future and supporting their partners through every stage of the product lifecycle. For additional information, visit radiopharmacy.com and connect with them on LinkedIn.
Over the last 18 months, TAG1 has diligently prototyped and incubated its generator design at esteemed facilities such as the Missouri University Research Reactor (MURR) and the Massachusetts Institute of Technology's Innovation Center (MITC). With the TAG1 Board's formal endorsement of the final clinical design, the company is poised to transition into the scaling and production phases. This strategy will allow TAG1 to provide high-purity Pb-212 through a decentralized, on-site generator model targeting radiopharmacies, hospitals, and therapeutic developers.
Sumit Verma, the CEO and Founder of TAG1, expressed optimism about the partnership, stating, "This collaboration with PharmaLogic is a defining step forward as we scale our Pb-212 generator technology. PharmaLogic's operational strength and commitment to innovation make them an ideal partner as we move from concept to clinic with a solution that supports both emerging and established radiotherapeutic programs."
The design of TAG1's Pb-212 generator closely resembles established models in nuclear medicine, enabling the on-demand, localized production of Pb-212. This decentralized model is crucial for alleviating supply bottlenecks associated with isotopes, especially as biopharmaceutical companies increasingly explore Pb-212-based therapies for oncology and rare diseases.
PharmaLogic's President and CEO, Etienne Montagut, shared his enthusiasm about the alliance, stating, "We're thrilled to support TAG1's next phase of growth and help expand access to alpha-emitting isotopes like Pb-212. As the demand for targeted radiotherapeutics surges, strategic partnerships are vital for connecting innovation with clinical delivery."
Having extensive expertise in radiopharmaceutical development, regulatory adherence, and large-scale manufacturing throughout North America, PharmaLogic is well-equipped to provide the operational support necessary for TAG1 to progress from prototype development to clinical-grade generator production. The firms will closely collaborate with pharmaceutical partners, academic institutions, and early innovators to ensure the on-demand delivery of preclinical and clinical quantities of Pb-212. This will be pivotal in supporting the next wave of advancements in targeted alpha therapy.
About TAG1 Inc.
TAG1 Inc. stands out as a prominent supplier of medical isotopes, particularly focusing on the production of Lead-212 (Pb-212) intended for use in Targeted Alpha Therapies (TATs). Their proprietary generator system is an innovative tool designed to unlock Pb-212 supplies for preclinical and clinical trials concerning targeted alpha therapies. Committed to revolutionizing cancer treatment via groundbreaking nuclear medicine, TAG1 Inc. aims to enhance the radiopharmaceutical supply chain and facilitate the development of cutting-edge therapies. Explore more at www.tag1inc.com and follow them on LinkedIn for updates.
About PharmaLogic Holdings Corp.
As a pioneering global CDMO, PharmaLogic specializes in both diagnostic and therapeutic radiopharmaceuticals. With decades of industry expertise and a vast network consisting of over 45 facilities across the U.S., Puerto Rico, Canada, and Norway, PharmaLogic offers all-encompassing solutions from development to manufacturing and distribution of both clinical and commercial-stage radiopharmaceutical products, adhering to the highest quality and regulatory standards. Their rapidly growing diagnostics business leverages cutting-edge technologies to improve patient access to novel diagnostics in critical areas such as oncology, cardiology, and neurology. In the therapeutic sector, PharmaLogic has secured its position as the only cGMP-compliant CDMO globally that manufactures and distributes a commercial radiopharmaceutical therapeutic to more than 30 countries. Dedicated to enhancing global patient access to radiopharmaceuticals, PharmaLogic pursues strategic development partnerships with industry innovators, driving the field's future and supporting their partners through every stage of the product lifecycle. For additional information, visit radiopharmacy.com and connect with them on LinkedIn.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.